Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11(1):2285. https://doi.org/10.1038/s41467-020-16164-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang JT, Lee YM, Huang RS. The impact of the Cancer Genome Atlas on lung cancer. Transl Res. 2015;166(6):568–85. https://doi.org/10.1016/j.trsl.2015.08.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–20. https://doi.org/10.1016/j.cell.2012.08.029.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Vaporciyan AA, Wistuba II, Swisher SG. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med. 2018;7(6):2405–14. https://doi.org/10.1002/cam4.1505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diwanji TP, Mohindra P, Vyfhuis M, Snider JW, Kalavagunta C, Mossahebi S, Yu J, Feigenberg S, Badiyan SN. Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Transl Lung Cancer Res. 2017;6(2):131–47. https://doi.org/10.21037/tlcr.2017.04.04.

Article  PubMed  PubMed Central  Google Scholar 

Liu D, Xu W, Ding X, Yang Y, Lu Y, Fei K, Su B. Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy. Cancer Biol Ther. 2017;18(12):948–57. https://doi.org/10.1080/15384047.2016.1276128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wieleba I, Wojas-Krawczyk K, Krawczyk P, Milanowski J. Clinical application perspectives of lung cancers 3D tumor microenvironment models for in vitro cultures. Int J Mol Sci. 2022;23(4). https://doi.org/10.3390/ijms23042261.

Fan Q, Wang Q, Cai R, Yuan H, Xu M. The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol Lett. 2020;25:1. https://doi.org/10.1186/s11658-019-0193-6.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Liu X, Zhang N, Yin M, Dong J, Zeng Q, Mao G, Song D, Liu L, Deng H. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5. Acta Pharm Sin B. 2020;10(12):2299–312. https://doi.org/10.1016/j.apsb.2020.06.014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang F, Wendusubilige Kong J, Zong Y, Wang M, Jing C, Ma Z, Li W, Cao R, Jing S, et al. Identifying oxidative stress-related biomarkers in idiopathic pulmonary fibrosis in the context of predictive, preventive, and personalized medicine using integrative omics approaches and machine-learning strategies. EPMA J. 2023;14(3):417–42. https://doi.org/10.1007/s13167-023-00334-4.

Article  PubMed  PubMed Central  Google Scholar 

Liu J, Shi Y, Zhang Y. Multi-omics identification of an immunogenic cell death-related signature for clear cell renal cell carcinoma in the context of 3P medicine and based on a 101-combination machine learning computational framework. EPMA J. 2023;14(2):275–305. https://doi.org/10.1007/s13167-023-00327-3.

Article  PubMed  PubMed Central  Google Scholar 

Kurysheva NI, Rodionova OY, Pomerantsev AL, Sharova GA, Golubnitschaja O. Machine learning-couched treatment algorithms tailored to individualized profile of patients with primary anterior chamber angle closure predisposed to the glaucomatous optic neuropathy. EPMA J. 2023;14(3):527–38. https://doi.org/10.1007/s13167-023-00337-1.

Article  PubMed  PubMed Central  Google Scholar 

Afrifa-Yamoah E, Adua E, Anto EO, Peprah-Yamoah E, Opoku-Yamoah V, Aboagye E, Hashmi R. Conceptualised psycho-medical footprint for health status outcomes and the potential impacts for early detection and prevention of chronic diseases in the context of 3P medicine. EPMA J. 2023;14(4):585–99. https://doi.org/10.1007/s13167-023-00344-2.

Article  PubMed  PubMed Central  Google Scholar 

Hu D, Shen X, Gao P, Mao T, Chen Y, Li X, Shen W, Zhuang Y, Ding J. Multi-omic profiling reveals potential biomarkers of hepatocellular carcinoma prognosis and therapy response among mitochondria-associated cell death genes in the context of 3P medicine. EPMA J. 2024;15(2):321–43. https://doi.org/10.1007/s13167-024-00362-8.

Article  PubMed  Google Scholar 

Li N, Zhan X. Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. EPMA J. 2020;11(3):485–504. https://doi.org/10.1007/s13167-020-00220-3.

Article  PubMed  PubMed Central  Google Scholar 

Hu X, Huang W, Sun Z, Ye H, Man K, Wang Q, Sun Y, Yan W. Predictive factors, preventive implications, and personalized surgical strategies for bone metastasis from lung cancer: population-based approach with a comprehensive cancer center-based study. EPMA J. 2022;13(1):57–75. https://doi.org/10.1007/s13167-022-00270-9.

Article  PubMed  PubMed Central  Google Scholar 

Zhang G, Wang Z, Song P, Zhan X. DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine. EPMA J. 2022;13(4):649–69. https://doi.org/10.1007/s13167-022-00300-6.

Article  PubMed  PubMed Central  Google Scholar 

Yang J, Ouedraogo S, Wang J, Li Z, Feng X, Ye Z, Zheng S, Li N, Zhan X. Clinically relevant stratification of lung squamous carcinoma patients based on ubiquitinated proteasome genes for 3P medical approach. EPMA J. 2024;15(1):67–97. https://doi.org/10.1007/s13167-024-00352-w.

Article  PubMed  Google Scholar 

Zhang J, Han X, Lin L, Chen J, Wang F, Ding Q, Hao L, Wang L, Wei J, Wang Y, Pan Y. Unraveling the expression patterns of immune checkpoints identifies new subtypes and emerging therapeutic indicators in lung adenocarcinoma. Oxid Med Cell Longev. 2022;2022:3583985. https://doi.org/10.1155/2022/3583985.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, Shang J, Gao J, Han H, Gao Z, Yan Y, Zheng Q, Ye T, Fu F, Deng C, et al. Increased tumor intrinsic growth potential and decreased immune function orchestrate the progression of lung adenocarcinoma. Front Immunol. 2022;13:921761. https://doi.org/10.3389/fimmu.2022.921761.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren X, Kang B, Zhang Z. Understanding tumor ecosystems by single-cell sequencing: promises and limitations. Genome Biol. 2018;19(1):211. https://doi.org/10.1186/s13059-018-1593-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Tan Y, Sun F, Hou L, Zhang C, Ge T, Yu H, Wu C, Zhu Y, Duan L, et al. Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer. Genome Biol. 2020;21(1):152. https://doi.org/10.1186/s13059-020-02064-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, et al. The single-cell immunogenomic landscape of B and plasma cells in early-stage lung adenocarcinoma. Cancer Discov. 2022;12(11):2626–45. https://doi.org/10.1158/2159-8290.CD-21-1658.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baba Y, Saito Y, Kotetsu Y. Heterogeneous subsets of B-lineage regulatory cells (Breg cells). Int Immunol. 2020;32(3):155–62. https://doi.org/10.1093/intimm/dxz068.

Article  CAS  PubMed  Google Scholar 

Patel AJ, Khan N, Richter A, Naidu B, Drayson MT, Middleton GW. Deep immune B and plasma cell repertoire in non-small cell lung cancer. Front Immunol. 2023;14:1198665. https://doi.org/10.3389/fimmu.2023.1198665.